- Home
- IBTA vs CERT Comparison
IBTA vs CERT Comparison
Compare IBTA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- CERT
- Stock Information
- Founded
- IBTA 2011
- CERT 2008
- Country
- IBTA United States
- CERT United States
- Employees
- IBTA N/A
- CERT N/A
- Industry
- IBTA
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- IBTA
- CERT Technology
- Exchange
- IBTA Nasdaq
- CERT Nasdaq
- Market Cap
- IBTA 892.4M
- CERT 1.7B
- IPO Year
- IBTA 2024
- CERT 2020
- Fundamental
- Price
- IBTA $26.61
- CERT $11.28
- Analyst Decision
- IBTA Hold
- CERT Buy
- Analyst Count
- IBTA 10
- CERT 7
- Target Price
- IBTA $44.33
- CERT $15.00
- AVG Volume (30 Days)
- IBTA 641.5K
- CERT 1.3M
- Earning Date
- IBTA 11-12-2025
- CERT 11-05-2025
- Dividend Yield
- IBTA N/A
- CERT N/A
- EPS Growth
- IBTA 2512.20
- CERT N/A
- EPS
- IBTA 2.84
- CERT 0.05
- Revenue
- IBTA $367,604,000.00
- CERT $405,755,000.00
- Revenue This Year
- IBTA N/A
- CERT $12.38
- Revenue Next Year
- IBTA $7.41
- CERT $7.49
- P/E Ratio
- IBTA $9.48
- CERT $226.96
- Revenue Growth
- IBTA 3.49
- CERT 11.61
- 52 Week Low
- IBTA $22.50
- CERT $8.64
- 52 Week High
- IBTA $79.80
- CERT $15.69
- Technical
- Relative Strength Index (RSI)
- IBTA 42.04
- CERT 56.35
- Support Level
- IBTA $25.59
- CERT $10.23
- Resistance Level
- IBTA $27.51
- CERT $11.09
- Average True Range (ATR)
- IBTA 1.20
- CERT 0.41
- MACD
- IBTA 0.46
- CERT 0.03
- Stochastic Oscillator
- IBTA 41.60
- CERT 88.33
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.